R. G. Hahn

3.5k total citations
45 papers, 1.9k citations indexed

About

R. G. Hahn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, R. G. Hahn has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in R. G. Hahn's work include Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (8 papers) and Gastric Cancer Management and Outcomes (6 papers). R. G. Hahn is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (8 papers) and Gastric Cancer Management and Outcomes (6 papers). R. G. Hahn collaborates with scholars based in United States. R. G. Hahn's co-authors include Allan J. Schutt, Richard J. Reitemeier, C G Moertel, Ronald H. Blum, Charles G. Moertel, D C Tormey, Avital Cnaan, Rajesh Ramanathan, Paul P. Carbone and David L. Ahmann and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

R. G. Hahn

42 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. G. Hahn United States 19 1.2k 643 396 310 280 45 1.9k
Don V. Jackson United States 27 1.3k 1.1× 508 0.8× 337 0.9× 219 0.7× 251 0.9× 75 2.0k
Frederick Richards United States 29 1.2k 1.0× 497 0.8× 457 1.2× 258 0.8× 319 1.1× 100 2.5k
Giuseppina Catalano Italy 28 1.4k 1.2× 835 1.3× 268 0.7× 377 1.2× 213 0.8× 72 2.2k
F. Ries Luxembourg 21 622 0.5× 325 0.5× 330 0.8× 171 0.6× 212 0.8× 70 1.7k
James B. Gerstner United States 18 1.6k 1.4× 544 0.8× 316 0.8× 305 1.0× 291 1.0× 29 2.1k
M Forni France 19 1.1k 1.0× 458 0.7× 526 1.3× 299 1.0× 124 0.4× 39 1.8k
Uğur Çoşkun Türkiye 26 862 0.7× 557 0.9× 535 1.4× 338 1.1× 221 0.8× 174 2.3k
F Crucitti Italy 25 868 0.8× 590 0.9× 200 0.5× 1.1k 3.5× 125 0.4× 103 2.1k
Stefan Madajewicz United States 20 875 0.8× 484 0.8× 236 0.6× 349 1.1× 91 0.3× 63 1.5k
Rajesh Ramanathan United States 24 1.1k 0.9× 465 0.7× 785 2.0× 467 1.5× 450 1.6× 87 2.3k

Countries citing papers authored by R. G. Hahn

Since Specialization
Citations

This map shows the geographic impact of R. G. Hahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. G. Hahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. G. Hahn more than expected).

Fields of papers citing papers by R. G. Hahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. G. Hahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. G. Hahn. The network helps show where R. G. Hahn may publish in the future.

Co-authorship network of co-authors of R. G. Hahn

This figure shows the co-authorship network connecting the top 25 collaborators of R. G. Hahn. A scholar is included among the top collaborators of R. G. Hahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. G. Hahn. R. G. Hahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wambach, G., et al.. (2008). Erhöhtes kardiovaskuläres Arteriosklerose-Risiko bei Analgetika-Nephropathie. DMW - Deutsche Medizinische Wochenschrift. 106(42). 1369–1373.
2.
Hahn, R. G., et al.. (2007). A Comparison of Unsedated Colonoscopy and Flexible Sigmoidoscopy in the Family Medicine Setting: An LA Net Study. The Journal of the American Board of Family Medicine. 20(5). 444–450. 9 indexed citations
3.
Yeap, B.Y., Thomas P. Davis, Ronald H. Blum, et al.. (1996). Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.. Journal of Clinical Oncology. 14(8). 2250–2257. 104 indexed citations
4.
5.
Borden, Ernest C., Kwang Taek Kim, Louise Ryan, et al.. (1992). Phase II Trials of Interferons-α and -β in Advanced Sarcomas. Journal of Interferon Research. 12(6). 455–458. 6 indexed citations
6.
7.
Patel, Shreyaskumar, Larry K. Kvols, R. G. Hahn, et al.. (1990). A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer. 66(4). 655–658. 24 indexed citations
8.
Kvols, Larry K., et al.. (1987). Treatment of the Malignant Carcinoid Syndrome. Survey of Anesthesiology. XXXI(3). 189–189. 62 indexed citations
9.
Ahmann, David L., Daniel J. Schaid, Harry F. Bisel, et al.. (1987). The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug.. Journal of Clinical Oncology. 5(12). 1928–1932. 53 indexed citations
10.
Hahn, R. G.. (1986). Clinical evaluation of flurbiprofen alone and plus ampicillin in chronic pharyngitis in acute phase.. PubMed. 6(1). 81–6. 4 indexed citations
11.
OʼConnell, M. J., C G Moertel, Larry K. Kvols, R. G. Hahn, & Joseph Rubin. (1986). Clinical Trial of Cisplatin and Intensive Course 5-Fluorouracil for the Treatment of Advanced Colorectal Cancer. American Journal of Clinical Oncology. 9(3). 192–195. 11 indexed citations
12.
Martínez, Alejandra, David L. Ahmann, William D. Payne, et al.. (1984). An interim analysis of the randomized surgical adjuvant trial for patients with unfavorable breast cancer. International Journal of Radiation Oncology*Biology*Physics. 10. 106–106. 18 indexed citations
13.
Frytak, Stephen, C G Moertel, Allan J. Schutt, R. G. Hahn, & Richard J. Reitemeier. (1975). Adriamycin (NSC-123127) therapy for advanced gastrointestinal cancer.. PubMed. 59(2 Pt 1). 405–9. 17 indexed citations
14.
Ahmann, David L., R. G. Hahn, Harry F. Bisel, Robert T. Eagan, & J H Edmonson. (1975). Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.. PubMed. 59(2 Pt 1). 451–3. 3 indexed citations
15.
Ahmann, David L., Charles G. Moertel, Harry F. Bisel, et al.. (1974). A Controlled Evaluation of 5-Fluorouracil Utilizing a Single Injection Technique. Oncology. 29(2). 166–171. 2 indexed citations
16.
Moertel, C G, Allan J. Schutt, Richard J. Reitemeier, & R. G. Hahn. (1972). Sequential 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and 5-fluorouracil (NSC 19893) therapy of gastrointestinal cancer.. PubMed. 32(6). 1280–2. 7 indexed citations
17.
Moertel, C G, Allan J. Schutt, Richard J. Reitemeier, & R. G. Hahn. (1972). Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.. PubMed. 56(1). 95–101. 231 indexed citations
18.
Moertel, Charles G., Richard J. Reitemeier, Allan J. Schutt, & R. G. Hahn. (1972). Treatment of the patient with adenocarcinoma of unknown origin. Cancer. 30(6). 1469–1473. 125 indexed citations
19.
Moertel, C G, Allan J. Schutt, Richard J. Reitemeier, & R. G. Hahn. (1972). Phase II study of 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in advanced gastrointestinal cancer.. PubMed. 56(2). 267–9. 1 indexed citations
20.
Moertel, C G, Richard J. Reitemeier, Allan J. Schutt, & R. G. Hahn. (1971). Phase II study of strepozotocin (NSC-85998) in the treatment of advanced gastrointestinal cancer.. PubMed. 55(3). 303–7. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Don V. Jackson Breakdown of academic impact, for papers by Frederick Richards Breakdown of academic impact, for papers by Giuseppina Catalano Breakdown of academic impact, for papers by F. Ries Breakdown of academic impact, for papers by James B. Gerstner Breakdown of academic impact, for papers by M Forni Breakdown of academic impact, for papers by Uğur Çoşkun Breakdown of academic impact, for papers by F Crucitti Breakdown of academic impact, for papers by Stefan Madajewicz Breakdown of academic impact, for papers by Rajesh Ramanathan
Rankless by CCL
2026